Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Mol Cell. 2018 Sep 20;71(6):1012-1026.e3. doi: 10.1016/j.molcel.2018.07.033. Epub 2018 Aug 30.
Pre-mRNA splicing is an essential step in the expression of most human genes. Mutations at the 5' splice site (5'ss) frequently cause defective splicing and disease due to interference with the initial recognition of the exon-intron boundary by U1 small nuclear ribonucleoprotein (snRNP), a component of the spliceosome. Here, we use a massively parallel splicing assay (MPSA) in human cells to quantify the activity of all 32,768 unique 5'ss sequences (NNN/GYNNNN) in three different gene contexts. Our results reveal that although splicing efficiency is mostly governed by the 5'ss sequence, there are substantial differences in this efficiency across gene contexts. Among other uses, these MPSA measurements facilitate the prediction of 5'ss sequence variants that are likely to cause aberrant splicing. This approach provides a framework to assess potential pathogenic variants in the human genome and streamline the development of splicing-corrective therapies.
前体 mRNA 剪接是大多数人类基因表达的一个必要步骤。由于 5' 剪接位点 (5'ss) 的突变干扰了 U1 小核核糖核蛋白 (snRNP) 对exon-intron 边界的初始识别,snRNP 是剪接体的一个组成部分,因此经常导致剪接缺陷和疾病。在这里,我们使用人类细胞中的大规模平行剪接分析 (MPSA) 来定量三种不同基因背景下所有 32768 个独特的 5'ss 序列 (NNN/GYNNNN) 的活性。我们的结果表明,尽管剪接效率主要由 5'ss 序列决定,但在不同的基因背景下,这种效率存在很大差异。除其他用途外,这些 MPSA 测量有助于预测可能导致异常剪接的 5'ss 序列变体。这种方法为评估人类基因组中潜在的致病性变体提供了一个框架,并简化了剪接纠正疗法的开发。